Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Albuferon albumin-interferon alpha: Final Phase IIb data

Final data from the open-label, international Phase IIb ALFR-HC-04 trial in 458 patients showed that those receiving 900 µg of Albuferon

Read the full 218 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE